Results 251 to 260 of about 103,862 (301)

Precision synergy: IDH and PARP inhibitors as a dual-target strategy in IDH-mutant glioma treatment. [PDF]

Ann Med Surg (Lond)
Shah MH, Ranganathan S, Thomson N, Dorcas AO.   +3 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study. [PDF]

Ther Adv Med Oncol
Peng X, Song R, Fan Y, Wang J, Li Q, Mo H, Wang J, Luo Y, Chen S, Sun X, Zhang J, Zhang P, Xu B, Lan B, Ma F.   +14 more
europepmc   +1 more source

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India. [PDF]

J Ovarian Res
Yeshala SK, Panda SS, Moharana L, Saju SV, Rathinam K, Raju SH, Sehrawat A, Sundriyal D, Phillip AO, Kinsely PA, Bhatia KP, Kayal S, Dubashi B, Cyriac SL, Natarajan S, Samantaray L, Mohanty SS, Sadangi S, Pradhan S, Rana A, Ganesan P.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tackling PARP inhibitor resistance

Trends in Cancer, 2021
Homologous recombination-deficient (HRD) tumours, including those harbouring mutations in the BRCA genes, are hypersensitive to treatment with inhibitors of poly(ADP-ribose) polymerase (PARPis). Despite high response rates, most HRD cancers ultimately develop resistance to PARPi treatment through reversion mutations or genetic/epigenetic alterations to
Fugger, Kasper, Hewitt, Graeme, West, Stephen C., Boulton, Simon J.   +3 more
openaire   +3 more sources

PARP Inhibitors

Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire   +2 more sources

Expanding biomarkers for PARP inhibitors

Nature Cancer, 2022
International audience ; The efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as targets for PARP inhibitors in breast cancer, whereas the added predictive value of HR signatures ...
Florence Coussy, Francois-Clement Bidard
openaire   +3 more sources

PARP inhibitor combination therapy

Critical Reviews in Oncology/Hematology, 2016
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality.
Dréan, A, Lord, CJ, Ashworth, A
openaire   +3 more sources

Adverse events of PARP inhibitors

Česká gynekologie, 2021
An evaluation of the safety of poly-ADP-ribose-polymerase inhibitors (PARPi) in ovarian cancer treatment.An analysis of the studies on PARP inhibitors, a summary of the most common and serious adverse events.According to the studies, the most common adverse events of PARPi include hematotoxicity, nausea and vomiting.
Martina, Romanová, Jaroslav, Klát
openaire   +2 more sources

PARP inhibitors coming of age

Nature Reviews Clinical Oncology, 2020
The much anticipated results from two phase III studies evaluating the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibition in patients with advanced-stage breast cancer harbouring a germline mutation in BRCA1/2 have established new therapeutic opportunities and yet, have left us with several ongoing questions.
Shani Paluch-Shimon, Fatima Cardoso
openaire   +2 more sources